Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With...

Area of Science:

• Urology
• Pharmacology

Background:

• Overactive bladder (OAB) significantly impacts quality of life.
• Behavioral therapy is a common OAB treatment.
• Mirabegron is a selective β3 adrenoceptor agonist for OAB treatment.

Purpose of the Study:

• To evaluate the therapeutic effects of behavioral therapy with or without mirabegron on OAB symptoms and sexual function in sexually active male patients.
• To assess mirabegron's potential to improve OAB symptoms and its impact on sexual function.

Main Methods:

• A 4-site randomized controlled trial enrolled 150 sexually active men with OAB.
• Participants were randomized to behavioral therapy alone (n=50) or mirabegron plus behavioral therapy (n=100).
• Outcomes included OABSS, sexual function scores, and urodynamic parameters, assessed at baseline, 4, and 12 weeks.

Main Results:

• Both groups showed significant improvement in OABSS after 12 weeks.
• The combination group demonstrated significant improvement in all OABSS subscores and functional bladder capacity.
• Urinary frequency and incontinence subscores did not significantly change in the behavioral therapy alone group.
• Neither treatment group exhibited significant changes in erectile or ejaculatory function.

Conclusions:

• Behavioral therapy combined with mirabegron demonstrated superior efficacy in improving OAB symptoms compared to behavioral therapy alone.
• Neither treatment approach significantly altered erectile or ejaculatory function in the study population.